Study of the drug “Kapikor” influence on the endothelial dysfunction in rats with doxorubicin cardiomyopathy

Authors

  • I. A. Zupanets National University of Pharmacy, Ukraine https://orcid.org/0000-0003-1253-9217
  • S. K. Shebeko National University of Pharmacy, Ukraine
  • I. A. Otrishko National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/ubphj.17.104

Keywords:

endothelial dysfunction, meldonium, gamma-butyrobetaine, doxorubicin cardiomyopathy

Abstract

Topicality. An alternative solution in terms of modern anti-ischemic therapy optimization is a combination of metabolic and hemodynamic concepts – joint use of precursors and carnitine analogs – meldonium and gamma-butyrobetaine (GBB). Pharmacodynamic benefits of these substances combined use are characterized by synergetic phenomenon in the form of mutual potentiation of their effects, it is displayed in the drug “Kapikor”.

Aim. The aim of this work was the experimental study of the drug “Kapikor” on endothelial dysfunction in rats with doxorubicin cardiomyopathy.

Materials and methods. The drug “Kapikor” and its cardioprotective properties study was carried out on the model of doxorubicin cardiomyopathy (DCM) in 90 white nonlinear rats.

Results and discussion. At the conditions of doxorubicin cardiomyopathy development it was shown that the cardioprotective properties of the drug “Kapikor” course, which is associated with the presence of metabolic, endothelialprotective, anti-ischemic, antihypoxic, antioxidant and anticytolitic, preconditioning activity. According to the combination of studied parameters in this disease model “Kapikor” excels the objects of comparison Mildronat and GBB.

Conclusions. The combined use of GBB and meldonium in the composition of “Kapikor” provides its monocomponents mutual modifying influence on indicators characterizing the inflammatory and destructive, degenerative-dystrophic and ischemic nature of myocardial dystrophy flow and has general protective influence on the cardioprotective effect level of the drug.

References

1. World Health Statistics 2012(2012). Geneva: WHO, 176.

2. European Detailed Mortality Database (2015). WHO, Regional Office for Europe. Available at: http://data.euro.who.int/dmdb.

3. Eurostat regional yearbook 2012 (2012). Luxembourg: Office of the European Union, 213.

White, A. (2011). The state of men’s health in Europe: extended report. European Union : European Commission. 401.

Dolzhenko, M. N. (2012). Mistetstvo lіkuvannia, 2–3, 3–6.

Zhitnikova, L. M. (2012). Russkii meditcinskii zhurnal, 20 (4), 137–143.

Sergienko, I. V. (2005). Atmosphera. Kardiologiia, 2, 43–45.

Arutiunov, G. P. (2015). Terapevticheskie aspekty diagnostiki i lecheniia zabolevanii serdtca i sosudov. Moscow: GEOTAR–Media, 608.

Belenkova, Ju. N., Oganova, R. G. (2007). Kardiologiia. Klinicheskie rekomendatcii. Moscow: GEOTAR–Media, 640.

Kovalenko, V. N. (2009). Rukovodstvo po kardiologii. Kiev: Morion, 1348.

Stephanov, A. V. (2002). Doklinicheskie issledovaniia lekarstvennyh sredstv. Kiev: Avitcenna, 528.

Semenov, A. N. (2001). Izuchenie kardioprotektornyh svoistv nesteroidnyh protivovospalitelnyh sredstv v riadu proizvodnyh D–(+)–gliukozamina. Kupavna, 26.

Rebrova, O. Ju. (2006). Statisticheskii analiz meditcinskih dannyh. Primenenie paketa prikladnyh programm STATISTICA, 3–e izd. Moscow: MediaSfera, 312.

Sergienko, V. I. (2006). Matematicheskaia statistika v klinicheskih issledovaniiah. Moskow: GEOTAR–Media, 304.

Truhacheva, N. V. (2012). Matematicheskaia statistika v mediko–biologicheskih issledovaniiah s primeneniem paketa Statistica. Moscow: GEOTAR–Media, 379.

Downloads

Published

2017-04-18

Issue

No. 2(49) (2017)

Section

Pharmacology and biochemistry

License

Copyright (c) 2017 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).